2020

Lieverse RIY, Van Limbergen EJ, Oberije CJG, Troost EGC, Hadrup SR, Dingemans AC, Hendriks LEL, Eckert F, Hiley C, Dooms C, Lievens Y, de Jong MC, Bussink J, Geets X, Valentini V, Elia G, Neri D, Billiet C, Abdollahi A, Pasquier D, Boisselier P, Yaromina A, De Ruysscher D, Dubois LJ, Lambin P.
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
BMC Cancer. 2020;20(1):557.

Troost EGC, Nestle U, Putora PM, Bussink J.
Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement.
Radiother Oncol. 2020;147:227-228.

Zwanenburg A, Vallières M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini L, Buvat I, Cook GJR, Davatzikos C, Depeursinge A, Desseroit MC, Dinapoli N, Dinh CV, Echegaray S, El Naqa I, Fedorov AY, Gatta R, Gillies RJ, Goh V, Götz M, Guckenberger M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leijenaar RTH, Lenkowicz J, Lippert F, Losnegård A, Maier-Hein KH, Morin O, Müller H, Napel S, Nioche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Socarras Fernandez J, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini V, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C, Löck S.
The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping.
Radiology. 2020;295(2):328-338.

Held KD, Lomax AJ, Troost EGC.
Proton therapy special feature: introductory editorial.
Br J Radiol. 2020;93(1107):20209004.

Jentsch C, Hofbauer C, Makocki S, Troost E.
Spätkomplikationen nach neo-/adjuvanter Strahlentherapie und Resektion von Sarkomen der Extremitäten oder des Beckens/Retroperitoneums : Ansätze zur Prävention [Late complications following neo-/adjuvant radiotherapy and surgery for sarcomas of the extremities or pelvis/retroperitoneum : Preventative measures].
Orthopade. 2020;49(2):177-182.

Wohlfahrt P, Möhler C, Enghardt W, Krause M, Kunath D, Menkel S, Troost EGC, Greilich S, Richter C.
Refinement of the Hounsfield look-up table by retrospective application of patient-specific direct proton stopping-power prediction from dual-energy CT.
Med Phys. 2020;47(4):1796-1806.

Zschaeck S, Li Y, Bütof R, Lili C, Hua W, Troost ECG, Beck M, Amthauer H, Kaul D, Kotzerke J, Baur ADJ, Ghadjar P, Baumann M, Krause M, Hofheinz F.
Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer.
Int J Cancer. 2020 Sep 1;147(5):1427-1436.

Putora PM, De Ruysscher D, Glatzer M, Widder J, Van Houtte P, Troost EGC, Slotman BJ, Ramella S, Pöttgen C, Peeters S, Nestle U, McDonald F, Le Pechoux C, Dziadziuszko R, Belderbos J, Faivre-Finn C.
The role of postoperative thoracic radiotherapy and prophylactic cranial irradiation in early stage small cell lung cancer: Patient selection among ESTRO experts.
Radiother Oncol. 2020;145:45-48.

Troost EGC, Wink KCJ, Roelofs E, Simone CB 2nd, Makocki S, Löck S, van Kollenburg P, Dechambre D, Minken AWH, van der Stoep J, Avery S, Jansen N, Solberg T, Bussink J, de Ruysscher D.
Photons or protons for reirradiation in (non-)small cell lung cancer: Results of the multicentric ROCOCO in silico  study.
Br J Radiol. 2020;93(1107):20190879.

Cubillos-Mesías M, Troost EGC, Lohaus F, Agolli L, Rehm M, Richter C, Stützer K.
Quantification of plan robustness against different uncertainty sources for classical and anatomical robust optimized treatment plans in head and neck cancer proton therapy.
Br J Radiol. 2020;93(1107):20190573.

2019

Eulitz J, Lutz B, Wohlfahrt P, Dutz A, Enghardt W, Karpowitz C, Krause M, Troost EGC, Lühr A.
A Monte Carlo based radiation response modelling framework to assess variability of clinical RBE in proton therapy.
Phys Med Biol. 2019 21;64(22):225020.

Eulitz J, Troost EGC, Raschke F, Schulz E, Lutz B, Dutz A, Löck S, Wohlfahrt P, Enghardt W, Karpowitz C, Krause M, Lühr A.
Predicting late magnetic resonance image changes in glioma patients after proton therapy.
Acta Oncol. 2019;58(10):1536-1539.

Wohlfahrt P, Möhler C, Troost EGC, Greilich S, Richter C.
Dual-Energy Computed Tomography to Assess Intra- and Inter-Patient Tissue Variability for Proton Treatment Planning of Patients With Brain Tumor.
Int J Radiat Oncol Biol Phys. 2019;105(3):504-513.

Apolle R, Appold S, Bijl HP, Blanchard P, Bussink J, Faivre-Finn C, Khalifa J, Laprie A, Lievens Y, Madani I, Ruffier A, de Ruysscher D, van Elmpt W, Troost EGC.
Inter-observer variability in target delineation increases during adaptive treatment of head-and-neck and lung cancer.
Acta Oncol. 2019 ;58(10):1378-1385.

Raschke F, Wesemann T, Wahl H, Appold S, Krause M, Linn J, Troost EGC.
Reduced diffusion in normal appearing white matter of glioma patients following radio(chemo)therapy.
Radiother Oncol. 2019;140:110-115.

Hölscher T, Lohaus F, Wirth M, Troost EGC. Reply to Piet R. Dirix, Carole Mercier, and Luc Y. Dirix's Letter to the Editor re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al.
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Eur Urol 2019;75:548-51. Eur Urol. 2019;76(4):e103-e104.

van Timmeren JE, Carvalho S, Leijenaar RTH, Troost EGC, van Elmpt W, de Ruysscher D, Muratet JP, Denis F, Schimek-Jasch T, Nestle U, Jochems A, Woodruff HC, Oberije C, Lambin P.
Challenges and caveats of a multi-center retrospective radiomics study: an example of early treatment response assessment for NSCLC patients using FDG-PET/CT radiomics.
PLoS One. 2019;14(6):e0217536.

Schneider S, Aust DE, Brückner S, Welsch T, Hampe J, Troost EGC, Hoffmann AL.
Detectability and structural stability of a liquid fiducial marker in fresh ex vivo pancreas tumour resection specimens on CT and 3T MRI.
Strahlenther Onkol. 2019;195(8):756-763.

Dolde K, Schneider S, Stefanowicz S, Alimusaj M, Flügel B, Saito N, Troost EGC, Pfaffenberger A, Hoffmann AL.
Comparison of pancreatic respiratory motion management with three abdominal corsets for particle radiation therapy: Case study.
J Appl Clin Med Phys. 2019;20(6):111-119.

Jentsch C, Troost EGC.
Wirksamkeit und Sicherheit einer Kohlenstoffionentherapie lokal rezidivierter Rektumkarzinome: Ergebnisse der J‑CROS-Studie 1404 Rektum [Efficacy and safety of carbon-ion radiotherapy for
locally recurrent rectal cancer: results of the J‑CROS Study 1404 Rectum].
Strahlenther Onkol. 2019;195(8):769-770.

Putora PM, Glatzer M, De Ruysscher D, Faivre-Finn C, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadiuszko R, Felip E, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, Brien MO, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, Slotman BJ.
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.
Radiother Oncol. 2019 Jun;135:74-77.

Löck S, Linge A, Seidlitz A, Bandurska-Luque A, Nowak A, Gudziol V, Buchholz F, Aust DE, Baretton GB, Zöphel K, Steinbach J, Kotzerke J, Overgaard J, Zips D, Krause M, Baumann M, Troost EGC.
Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Radiother Oncol. 2019;135:43-50.

Wagner F, Hölig U, Wilczkowski F, Plesca I, Sommer U, Wehner R, Kießler M, Jarosch A, Flecke K, Arsova M, Tunger A, Bogner A, Reißfelder C, Weitz J, Schäkel K, Troost EGC, Krause M, Folprecht G, Bornhäuser M, Bachmann MP, Aust D, Baretton G, Schmitz M.
Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc Monocytes in Rectal Cancer.
Front Immunol. 2019;10:602.

Apolle R, Brückner S, Frosch S, Rehm M, Thiele J, Valentini C, Lohaus F, Babatz J, Aust DE, Hampe J, Troost EGC.
Utility of fiducial markers for target positioning in proton radiotherapy of oesophageal carcinoma.
Radiother Oncol. 2019;133:28-34.

Putora PM, Glatzer M, Belderbos J, Besse B, Blackhall F, Califano R, Cappuzzo F, de Marinis F, Dziadziuszko R, Felip E, Faivre-Finn C, Früh M, Garrido P, Le Pechoux C, McDonald F, Nestle U, Novello S, O'Brien M, Paz Ares L, Peeters S, Pöttgen C, Ramella S, Reck M, Slotman B, Troost EGC, Van Houtte P, Westeel V, Widder J, Mornex F, De Ruysscher D.
Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts.
Radiother Oncol. 2019;133:163-166.

Dutz A, Agolli L, Baumann M, Troost EGC, Krause M, Hölscher T, Löck S.
Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis.
Acta Oncol. 2019;58(6):916-925.

van der Heyden B, Wohlfahrt P, Eekers DBP, Richter C, Terhaag K, Troost EGC, Verhaegen F.
Dual-energy CT for automatic organs-at-risk segmentation in brain- tumor patients using a multi-atlas and deep-learning approach.
Sci Rep. 2019;9(1):4126.

Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Perrin R, Appold S, Krause M, Steinbach J, Kotzerke J, Hofheinz F, Zips D, Baumann M, Troost EGC.
Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients.
Clin Transl Radiat Oncol. 2019;15:108-112.

Schmidt J, Appold S, Troost EGC.
Einfluss der prophylaktischen Ganzhirnbestrahlung auf das Gesamtüberleben von Patienten mit einem fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom [Impact of prophylactic cranial irradiation on overall survival of patients with advanced non-small-cell lung cancer].
Strahlenther Onkol. 2019;195(5):453-456.

Cubillos-Mesías M, Troost EGC, Lohaus F, Agolli L, Rehm M, Richter C, Stützer K.
Including anatomical variations in robust optimization for head and neck proton therapy can reduce the need of adaptation.
Radiother Oncol. 2019;131:127-134.

Wink KCJ, Löck S, Rossi M, van Baardwijk A, Belderbos J, de Ruysscher D, Troost EGC.
Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
Radiother Oncol. 2019;131:120-126.

Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost EGC, Meier F.
Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.
Eur J Cancer. 2019;110:11-20.

Zwanenburg A, Leger S, Agolli L, Pilz K, Troost EGC, Richter C, Löck S.
Assessing robustness of radiomic features by image perturbation.
Sci Rep. 2019;9(1):614.

Lohaus F, Zöphel K, Löck S, Wirth M, Kotzerke J, Krause M, Baumann M, Troost EGC, Hölscher T.
Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
Eur Urol. 2019 ;75(4):548-551.

Eekers DBP, Roelofs E, Cubillos-Mesías M, Niël C, Smeenk RJ, Hoeben A, Minken AWH, Granzier M, Janssens GO, Kaanders JHAM, Lambin P, Troost EGC.
Intensity-modulated proton therapy decreases dose to organs at risk in low-grade glioma patients: results of a multicentric in silico ROCOCO trial.
Acta Oncol. 2019;58(1):57-65.

Langendijk JA, Troost EGC, Haustermans K, Grau C, Weber DC.
Reply to Laprie A. et al.
Radiother Oncol. 2019;130:194.

Kurz C, Süss P, Arnsmeyer C, Haehnle J, Teichert K, Landry G, Hofmaier J, Exner F, Hille L, Kamp F, Thieke C, Ganswindt U, Valentini C, Hölscher T, Troost E, Krause M, Belka C, Küfer KH, Parodi K, Richter C.
Dose-guided patient positioning in proton radiotherapy using multicriteria-optimization.
Z Med Phys. 2019;29(3):216-228.

Bandurska-Luque A, Löck S, Haase R, Richter C, Zöphel K, Abolmaali N, Seidlitz A, Appold S, Krause M, Steinbach J, Kotzerke J, Zips D, Baumann M, Troost EGC.
FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Radiother Oncol. 2019;130:97-103.

Leger S, Zwanenburg A, Pilz K, Zschaeck S, Zöphel K, Kotzerke J, Schreiber A, Zips D, Krause M, Baumann M, Troost EGC, Richter C, Löck S.
CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer.
Radiother Oncol. 2019 ;130:10-17.

Dutz A, Lühr A, Agolli L, Troost EGC, Krause M, Baumann M, Vermeren X,Geismar D, Schapira EF, Bussière M, Daly JE, Bussière MR, Timmermann B, Shih HA, Löck S.
Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours.
Radiother Oncol. 2019;130:164-171.

2018

D. L. Bailey, B. J. Pichler, B. Gückel, G. Antoch, H. Barthel, Z. M. Bhujwalla, S. Biskup, ..., E. Troost, u. a. „Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany“. Molecular Imaging and Biology, 20, Nr. 1 (2018): 4–20.

Sara Carvalho, Ralph T. H. Leijenaar, Esther G. C. Troost, Janna E. van Timmeren, Cary Oberije, Wouter van Elmpt, Lioe-Fee de Geus-Oei, Johan Bussink, und Philippe Lambin. „18F-Fluorodeoxyglucose Positron-Emission Tomography (FDG-PET)-Radiomics of Metastatic Lymph Nodes and Primary Tumor in Non-Small Cell Lung Cancer (NSCLC) - A Prospective Externally Validated Study“. PloS One 13, Nr. 3 (2018): e0192859.


Almut Dutz, Esther G. C. Troost, und Steffen Löck. „Proton therapy not superior to IMRT in locally advanced NSCLC“. Strahlentherapie Und Onkologie: Organ Der Deutschen Röntgengesellschaft, 194, 8 (2018): 790–93.


Daniëlle B. P. Eekers, Lieke In’t Ven, Sabine Deprez, Linda Jacobi, Erik Roelofs, Ann Hoeben, Philippe Lambin, Dirk de Ruysscher, und Esther G. C. Troost. „The Posterior Cerebellum, a New Organ at Risk?“ Clinical and Translational Radiation Oncology 8 (2018): 22–26.

Daniëlle B. P. Eekers, Esther N. Pijnappel, Olaf E. M. G. Schijns, Albert Colon, Ann Hoeben, Jaap D. Zindler, Alida A. Postma, Aswin L. Hoffmann, Philippe Lambin, und Esther G. C. Troost. „Evidence on the Efficacy of Primary Radiosurgery or Stereotactic Radiotherapy for Drug-Resistant Non-Neoplastic Focal Epilepsy in Adults: A Systematic Review“. Seizure 55 (2018): 83–92.

Daniëlle B.P. Eekers, Lieke In’t Ven, Erik Roelofs, Alida Postma, Claire Alapetite, Neil G. Burnet, Valentin Calugaru, ..., Esther Troost, u. a. „The EPTN Consensus-Based Atlas for CT- and MR-Based Contouring in Neuro-Oncology“. Radiotherapy and Oncology, 128, 1 (2018): 37–43.

Susanne Frosch, und Esther G. C. Troost. „Concurrent once-daily or twice-daily chemoradiotherapy in limited-stage small-cell lung cancer?“. Strahlentherapie Und Onkologie: Organ Der Deutschen Röntgengesellschaft, 194, 1 (2018): 73–75.

Andreas Gommlich, Felix Raschke, Hannes Wahl, und Esther G. C. Troost. „Retrospective Assessment of MRI-Based Volumetric Changes of Normal Tissues in Glioma Patients Following Radio(Chemo)Therapy“. Clinical and Translational Radiation Oncology 8 (2018): 17–21.

Marvin Kuske, Ricarda Rauschenberg, Marlene Garzarolli, Michelle Meredyth-Stewart, Stefan Beissert, Esther G. C. Troost, Oliva Isabella Claudia Glitza, und Friedegund Meier. „Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges“. American Journal of Clinical Dermatology 19, 4 (2018): 529–41.

Maarten Lambrecht, Daniëlle B. P. Eekers, Claire Alapetite, Neil G. Burnet, Valentin Calugaru, Ida E. M. Coremans, Piero Fossati, ..., Esther Troost, u. a. „Radiation Dose Constraints for Organs at Risk in Neuro-Oncology; the European Particle Therapy Network Consensus“. Radiotherapy and Oncology, 128, 1 (2018): 26–36.

Johannes A. Langendijk, Roberto Orecchia, Karin Haustermans, Daniel Zips, Jacques Balosso, Denis Lacombe, Yolande Lievens, Damien C. Weber, Cai Grau, und Esther G. C. Troost. „Prospective Data Registration and Clinical Trials for Particle Therapy in Europe“. Radiotherapy and Oncology, 128, 1 (2018): 9–13.

Armin Lühr, Cläre von Neubeck, Mechthild Krause, und Esther G. C. Troost. „Relative Biological Effectiveness in Proton Beam Therapy - Current Knowledge and Future Challenges“. Clinical and Translational Radiation Oncology 9 (2018): 35–41.

Jan Petr, Ivan Platzek, Frank Hofheinz, Henri J. M. M. Mutsaerts, Iris Asllani, Matthias J. P. van Osch, Annekatrin Seidlitz, ..., Esther Troost, u. a. „Photon vs. Proton Radiochemotherapy: Effects on Brain Tissue Volume and Perfusion“. Radiotherapy and Oncology, 128, 1 (2018): 121–27.

Sergej Schneider, Rasmus Irming Jølck, Esther Gera Cornelia Troost, und Aswin Louis Hoffmann. „Quantification of MRI Visibility and Artifacts at 3T of Liquid Fiducial Marker in a Pancreas Tissue-Mimicking Phantom“. Medical Physics 45, 1 (2018): 37–47.

Krista C. J. Wink, Erik Roelofs, Charles B. Simone, David Dechambre, Alina Santiago, Judith van der Stoep, Wim Dries, ..., Esther Troost, u.a. "Photons, Protons or Carbon Ions for Stage I Non-Small Cell lung Cancer - results of the Multicentric ROCOCO in Silico Study". Radiotherapy and Oncology, 128, 1 (2018) 139-46.

 

2015

Erven AJG, van der Stoep J, Zegers K, Reymen B, Lambin P, Troost EGC, van Elmpt W. PET-based dose painting in non-small cell lung cancer: comparing uniform dose escalation with boosting hypoxic and metabolically active sub-volumes. Accepted for publication in Radiother Oncol.

Hendriks LE, Derks J, Postmus PE, Damhuis RA, Houben RM, Troost EGC, Hochstenbag MM, Smit EF, Dingemans AM. Single organ metastatic disease, a new prognostic factors in stage IV Non-Small Cell Lung Cancer. Accepted for publication in Eur J Cancer.

Hermans BCM, Persoon LC, Hoebers FJP, Verhaegen F, Troost EGC. Weekly cone beam computed tomography for detection of discrepancies between planned and delivered dose in head and neck cancer patients treated with radical (chemo)radiotherapy. E-pub ahead of print in Acta Oncol.

Jentsch C, Beuthien-Baumann B, Troost EGC, Shakirin G (2015) Validation of functional imaging results as a biomarker for radiation treatment response. Br J Radiol 88: 20150014

Leijenaar RTH, Nalbantov G, Carvalho S, van Elmpt WJC, Troost EGC, Boellaard R, Aerts HJWL, Lambin P. The effect of SUV discretization in quantitative FDG-PET Radiomics: the need for standardized methodology in tumor texture analysis. Accepted for publication in Nature Scientific Reports.

Persoon LCGG, Podesta M, Hoffmann L, Sanizadeh A, Schyns LEJR, de Ruiter B, Nijsten SMJJG, Muren LP, Troost EGC, Verhaegen F. Is integrated transit planar portal dosimetry able to detect geometric changes in lung cancer patients treated with volumetric modulated arc therapy? E-pub ahead of print in Acta Oncol.

Schimek-Jasch T, Troost EGC, Rücker G, Prokic V, Avlar M, Duncker-Rohr V, Mix M, Doll C, Gorsu AL, Nestle U (2015) A teaching intervention in a contouring dummy run for a multicentre clinical study improved target volume delineation in locally advanced non-small cell lung cancer. Strahlenth Onkol: 525-533

Troost EGC, Hoeben BAW, Laverman P, Bussink J, Oyen WJG (2015) In response to “Histopathologic validation of 3’-deoxy-3’-18F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude mice”. Radiother Oncol 114: 417-418

van Elmpt W, Zegers CML, Reymen B, Even A, Dingemans AMC, Oellers M, Wildberger J, Mottaghy F, Das M, Troost EGC, Lambin P. Multi-parametric imaging of hypoxic, metabolic and perfusion tumour characteristics of non-small cell lung cancer patients for tumour heterogeneity quantification. Accepted for publication in Eur J Nucl Med Molec Imaging.

Wijsman R, Dankers F, Troost EGC, Hoffmann AL, Van der Heijden EHFM, de Geus-Oei LF, Bussink J. Predicting acute esophageal toxicity in advanced stage non-small cell lung cancer patients treated with intensity-modulated (chemo-) radiation. Accepted for publication in Radiother Oncol.

Wink K, Roelofs E, Solberg T, Lin L, Simone CB, Jakobi A, Richter C, Lambin P, Troost EGC (2015) Particle therapy for non-small cell lung tumors: where do we stand? A systematic review of the literature. Radiat Oncol: 292

Zegers CML, Rekers NH, Quaden DHF, Lieuwes NG, Yaromina A, Germeraad WTV, Wieten L, Biessen E, Neri D, Troost EGC, Dubois L, Lambin P (2015) Radiotherapy combined with targeted immunotherapy (L19-IL2) results in long-lasting anti-tumor effects. Clin Cancer Res: 1151-1160

Zegers CML, Van Elmpt, W, Hoebers FJP, Troost EGC, Öllers MC, Mottaghy F, Lambin P. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma. E-pub ahead of print in Acta Oncol.

 

 

2014

Arens AIJ*, Troost EGC*, Hoeben BAW, Visvikis D, Bussink J, Oyen WJG, Kaanders JHAM, Visser EP (2014) Comparison of multiple (semi-)automatic segmentation methods for delineation of proliferative head and neck tumor volume in sequential FLT PET/CT imaging. Eur J Nucl Med Mol Imag 41: 915-924, *shared first author

Hendriks LEL, Troost EGC, Steward A, Bootsma G, de Jaeger K, van den Borne B, Dingemans AMC (2014) Impact of new Dutch guideline on brain metastases on patient selection for whole brain radiotherapy in a large lung cancer cohort. Acta OncoI 53: 945-951

Hoeben BAW, Bussink J, Troost EGC, Oyen WJG, Kaanders JHAM (2014) PET voor adaptatie van radiotherapieplanning bij hoofd-hals carcinomen. NederlandsTijdschrift voor Oncologie 11: 261-267 (Dutch)

Hoeben BAW, Troost EGC, Bussink J, van Herpen CM, Oyen WJG, Kaanders JHAM (2014) 18F-FLT PET changes during Radiotherapy combined with Cetuximab in Head and Neck Squamous Cell Carcinoma Patients. Nuklearmedizin 53: 60-66

Rekers NH*, Troost EGC*, Zegers CML, Germeraad WTV, Dubois L, Lambin P (2014) Bi-modal treatment consisting of radiotherapy and immunotherapy; what’s the present status? Cancer Radiotherapie 18: 391-395, *shared first author

Smits KM, Melotte V, Niessen HEC, Dubois L, Oberije C, Troost EGC, Starmans M, Vooijs M, van Engeland M, Lambin P (2014) Epigenetic biomarkers in radiotherapy: the current status. Radiother Oncol 111: 168-177

Troost EGC (2014) Stereotaktische Radiotherapie voor Oligometastasen. Van palliatieve behandeling naar curatieve intentie. Oncology News International

Van De Voorde L, Pijls M, Sosef M, Larue R, Berbée M, Troost EGC, Schraepen MC, Oellers M, Lambin P (2014) A qualitative synthesis of the evidence behind elective lymph node irradiation in oesophageal cancer. Radiother Oncol 113: 166-174

Van De Voorde L, Vanneste B, Borger J, Troost EGC, Werner P (2014) Rapid decline of follicular lymphoma-associated chylothorax after low dose radiotherapy to retroperitoneal lymphoma localization. Case Reports in Hematology: ID 684689

 

 

2013

Carvalho S, Leijenaar R, Rios Velazquez E, Oberije C, Van Elmpt W, Reymen B,  Troost EGC, Aerts HJWL, Lambin P (2013) Prognostic usefulness of metabolic metrics extracted from baseline PET images in NSCLC. Acta Oncol 52: 1398-1404

Hoeben BAW, Bussink J, Troost EGC, Oyen WJG and Kaanders JHAM (2013) Molecular PET Imaging for Biology-Guided Adaptive Radiotherapy of Head and Neck Cancer. Acta Oncol 52: 1257-1271

Hoeben BAW*, Troost EGC*, van Herpen CM, Bussink J, Oyen WJG, Kaanders JHAM (2013) 18FLT-PET is an early predictor of long-term outcome during (chemo)radiotherapy in head and neck cancer patients. J Nucl Med 54: 532-540, *shared first author

Hoebers F, Rios E, Troost EGC, van den Ende P, Kross K, Lacko M, Lalisang R, Kremer B, de Jong J (2013) Definitive radiation therapy for treatment of laryngeal carcinoma: Impact of local relapse on outcome and implications for treatment strategies. Strahlenther Onkol 189: 834-841

Lambin P, Roelofs E, Reymen B, Rios Velazquez E, Buijsen J, Zegers K, Carvalho S, Leijenaar R, Nalbantov G, Oberije C, Marshall S, Hoebers F, Troost EGC, van Stiphout RGPM, van Elmpt W, van der Weijden T, Boersma L, Valentini V, Dekker A (2013) ‘Rapid Learning Health Care in Oncology’ – An approach towards decision support systems allowing customised radiotherapy. Radiother Oncol 109: 159-164

Mönnich D, Troost EGC, Kaanders JHAM, Oyen WJG, Alber M, Zips D, Thorwarth D (2013) Correlation between tumor oxygenation and 18F-Fluoromisonidazole PET data simulated based on microvessel images. Acta Oncol 52: 1308-1313

Nalbantov G, Kietselaer B, Vandecasteele K, Oberije C, Berbee M, Troost EGC, Dingemans AM, van Baardwijk A, Reymen B, Smits KM, Dekker A, Bussink J, Lievens Y, Lambin P (2013) Cardiac comorbidity is an independent risk factor for radiation-induced lung toxicity in lung cancer patients. Radiother Oncol 109: 100-106

Persoon LCGG, Egelmeer AGTM, Öllers MC, Nijsten SMJJG, Troost EGC, Verhaegen F (2013) First clinical results of adaptive radiotherapy based on 3D portal dosimetry for lung cancer patients with atelectasis treated with Volumetric Modulated Arc Therapy (VMAT). Acta Oncol 52: 1484-1489

Troost EGC, Hoeben BAW, Span PN, van Herpen CML, Bussink J, Arens AIJ, Oyen WJG, Kaanders JHAM (2013) FLT-PET gedurende (chemo)radiotherapie als vroegtijdige voorspeller van behandeluitkomst bij hoofd-hals-tumoren. NederlandsTijdschrift voor Oncologie 10: 308-317 (Dutch)

Troost EGC, Hoffmann AL, Bussink J (2013) Balancing radiation pneumonitis versus locoregional tumor control in non-small cell lung cancer. JTO 8: e35-e36

Usmanij EA, de Geus-Oei LF, Troost EGC,  Peters-Bax L, van der Heijden HFM, Kaanders JHAM, Oyen WJG, Schuurbiers OCJ, Bussink J (2013) 18F-FDG-PET Early Response Evaluation of Locally Advanced Non-Small Cell Lung Cancer treated with Concomitant Chemo-Radiotherapy. J Nucl Med 54: 1528-1534

van Elmpt W, Das M, Hüllner M, Sharifi H, Zegers K, Reymen B, Lambin P, Wildberger JE, Troost EGC, Veit-Haibach P, De Ruysscher D. Characterization tumour heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer (2013) Radiother Oncol 109: 65-70

Van Gestel K, Buurman DJM, Pijls R, Hoffmann AL, Troost EGC. HDR-brachytherapy instead of hemi-maxillectomy for a patient with locally advanced verrucous carcinoma of the oral cavity (2013) Strahlenther Onkol 189: 894-898

Zegers CML, Van Elmpt W, Wierts R,  Sharifi H, Reymen B, Öllers MC, Hoebers F, Troost EGC, Wanders S, Van Baardwijk A, Eriksson J, Windhorst B , Mottaghy FM, De Ruysscher D, Lambin P (2013) Hypoxia imaging with [18F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol 109: 58-64

 

 

2012

Govaert SLA, Troost EGC, Schuurbiers OCJ, de Geus-Oei LF, Termeer A, Span PN, Bussink J (2012) Treatment outcome and toxicity of intensity-modulated (chemo)radiotherapy in stage III non-small cell lung cancer patients. Radiat Oncol 7: 150

Hoffmann AL, Troost EGC, Huizenga H, Kaanders JHAM, Bussink J (2012) Individualized dose prescription for hypofrationation in advanced non-small cell lung cancer radiotherapy: an in silico trial. Int J Radiat Oncol Biol Phys 83: 1596-1602

Idema AJ, Hoffmann AL, Troost EGC, Boogaarts HD, Wesseling P, Heerschap A, van der Graaf WTA, Grotenhuis JA, Oyen WJG (2012) 18F-Fluorothymidine (FLT) Positron Emission Tomography-derived proliferative tumor volume predicts survival in high-grade glioma patients. J Nucl Med 53: 1904-1910

Mönnich D, Troost EGC, Kaanders JHAM, Oyen WJG, Alber M, Thorwarth D (2012) Modelling and simulation of the influence of acute and chronic hypoxia on [18F]Fluoromisonidazole PET imaging. Phys Med Biol 57: 1675-1684

Zegers C, Reymen R, Buijsen J, van Stiphout R, Peeters S, Lammering G, Hoebers F, Troost EGC, van Baardijk A, Oellers M, van Elmpt W, Lambin P (2012) De bijdrage van PET-beeldvorming in radiotherapie. Het voorbeeld van long- en rectumkanker. Kanker Breed 4: 18-21 (Dutch)

 

 

2011

Aarntzen EHJG, Srinivas M, Jacobs, HJF, Lesterhuis WJ, Windhorst B, Troost EGC, van Rossum M, Boerman OC, Punt CJA, Figdor CF, Oyen, WJG, de Vries J (2011) [18F]FLT PET for in vivo functional imaging of antigen specific immune responses in humans. Proc Natl Acad Sci 108: 18396-18399

Arens AIJ*, Troost EGC*, Schinagl DAX, Kaanders JHAM, Oyen WJG (2011) FDG-PET/CT in radiation treatment planning of head and neck squamous cell carcinoma. Quart J Nucl Med Mol Imaging 55: 521-528, *shared first author

Mönnich D, Troost EGC, Kaanders JHAM, Oyen WJG, Alber M, Thorwarth D (2011) Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps. Phys Med Biol 56: 2045-2057

Troost EGC (2011) Proefschriftbespreking “Validation of PET imaging for non-invasive characterization of head and neck tumors”. NederlandsTijdschrift voor Oncologie 8: 44-46 (Dutch)

 

 

2010

Hoeben BAW, Kaanders JHAM, Franssen GM, Troost EGC, Rijken PFJW Oosterwijk E, van Dongen GAMS, Oyen WJG, Boerman OC, Bussink J (2010) PET of hypoxia with 89Zr-labeled cG250-F(ab’)2 in head and neck tumors. J Nucl Med 51: 1076-1083

Troost EGC (2010) Proefschriftbespreking “Validation of PET imaging for non-invasive characterization of head and neck tumors”. Hoofd-Hals Journaal 22: 39 (Dutch)

Troost EGC (2010) Validation of PET imaging for non-invasive characterization of head and neck tumors. Proefschriftbespreking. Tijdschr Nucl Geneesk 32: 512-513 (Dutch)

Troost EGC, Bussink J, Hoffmann AL, Boerman OC, Oyen WJG, Kaanders JHAM (2010) 18FLT-PET-CT for early response monitoring and dose escalation in oropharyngeal tumor. J Nucl Med 51: 866-874

Troost EGC, Bussink J, Slootweg PJ, Peeters WJM, Merkx MAW, van der Kogel AJ, Oyen WJG, Kaanders JHAM (2010) Histopathological validation of 18FLT-PET in squamous cell carcinoma of the oral cavity. J Nucl Med 51: 713-719

Troost EGC, Schinagl DAX, Bussink J, Oyen WJG, Boerman OC, Kaanders JHAM (2010) Correlation of segmented metabolic tumor volume with outcome. In response to Chung et al. Clin Cancer Res 16: 1968

Troost EGC, Schinagl DAX, Bussink J, Boerman OC, van der Kogel AJ, Oyen WJG, Kaanders JHAM (2010) Innovations in radiotherapy planning of head and neck cancers: role of PET imaging. J Nucl Med 51: 66-76

Troost EGC, Schinagl DAX, Bussink J, Oyen WJG, Kaanders JHAM (2010) Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours. Radiother Oncol 96: 328-334

 

 

2009

Schinagl DAX, Troost EGC, Kaanders JHAM (2009) Combined 18FDG-PET/CT imaging in radiotherapy target delineation for head and neck cancer. In response to Guido et al. Int J Radiat Oncol Biol Phys 74: 1629

Troost EGC, Bussink J, Oyen WJG, Kaanders JHAM (2009) 18F-FDG and 18F-FLT do not discriminate between reactive and metastatic lymph nodes in oral cancer patients. In response to Nagakawa et al. J Nucl Med 50: 490-491

Troost EGC, Oyen WJG, Kaanders JHAM (2009) The role of PET in radiotherapy of head and neck cancers. Tijdschr Nucl Geneesk 31: 403-410 (Dutch)

 

 

2008

Troost EGC, Laverman P, Kaanders JHAM, Oyen WJG, Boerman OC, Bussink J (2008) Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18FAZA and 125I-Gluco-RGD autoradiography. In response to Picchio et al. J Nucl Med 49: 1732

Troost EGC, Laverman P, Philippens MEP, Bussink J, van der Kogel AJ, Oyen WJG, Boerman OC, Kaanders JHAM (2008) Correlation of 18FMISO autoradiography and pimonidazole immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 35: 1803-1811

 

 

2007

Troost EGC, Bussink J, Kaanders JHAM (2007) Inhibitie van EGFR bij bestraling van plaveiselcelcarcinomen in het hoofd- halsgebied. Ned Tijdschr Kanker 31: 14-18 (Dutch)

Troost EGC, Vogel WV, Merkx MAW, Slootweg PJ, Marres HAM, Peeters WJM, Bussink J, van der Kogel AJ, Oyen WJG, Kaanders JHAM. 18FLT-PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients (2007) J Nucl Med 48: 726-735

 

 

2006

Troost EGC, Laverman P, Kaanders JHAM, Philippens MEP, Lok J, Oyen WJG, van der Kogel AJ, Boerman OC, Bussink J (2006) Imaging hypoxia after oxygenation-modification: comparing 18FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumours. Radiother Oncol 80: 157-164

 

 

2005

Troost EGC, Bussink J, Kaanders JHAM, van Eerd JEM, Peters JPW, Rijken PFJW, Boerman OC, van der Kogel AJ (2005) Comparison of different methods of CA-IX quantification in relation to hypoxia in three human head and neck tumour lines. Radiother Oncol 76: 194-199

 

 

2003

Troost EGC, Hold GL, Smith MG, Mowat A, Chow W-H, Rabkin CS, El-Omar EM (2003) The role of interleukin-1beta and other potential genetic markers as indicators of gastric cancer risk. Can J Gastroenterol 17: 8B-12B

Troost EGC, Hold GL, Smith MG, Mowat A, Chow W-H, Rabkin CS, El-Omar EM (2003) The role of interleukin-1beta and other potential genetic markers as indicators of gastric cancer risk. Helicobacter pylori: Basic Mechanisms to Clinical Cure, Editors Hunt RH & Tytgat GNJ, Kluwer Academic Publishers: 215-223